GenoMed, Inc. Signs Letter of Intent for Distribution of Its Clinical Outcomes Improvement Program(TM) to Brazil
ST. LOUIS, Mo., Aug. 27 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has signed a Letter of Intent with Dr. Mario Abbud-Filho to introduce its Clinical Outcomes Improvement Program(TM) to physicians in Brazil.
Dr. Abbud-Filho is a leading academic nephrologist and expert in kidney transplantion practicing in Sao Paolo, the most populous state in Brazil. Dr. Abbud-Filho is currently a tenured professor at the Medical School of Rio Preto, where he went to medical school, and where he recently served as Vice- Director. After finishing his nephrology training in Brazil, he spent two years in Paris and two additional years at Harvard Medical School as a post- graduate researcher in transplantation immunology. He is a former Executive Director of the Brazilian Transplant Organ Association, and currently serves as Editor-in-Chief of two medical journals, the Brazilian Transplantation Journal and the Medical Journal of the Medical School of Rio Preto.
Dr. Abbud-Filho stated that, "It is appropriate that Brazil has been designated as one of the countries for GenoMed's medical genomics effort. Brazil is the economic and population giant of South America and is larger than the United States. Our President has made affordable, state-of-the-art health care a national priority. Brazilian physicians have long been interested in embracing the best available medicine. Collaboration with GenoMed will allow our physicians to bring the benefits of the Genomic Revolution to their patients and will help supplement their income as well. The GenoMed program delivers enormous value for all concerned."
Under the proposed agreement, Dr. Abbud-Filho will help introduce and support GenoMed's Clinical Outcomes Improvement Program(TM) to physicians in Sao Paolo and elsewhere in Brazil.
Dr. David Moskowitz, GenoMed's Chairman, said, "We are delighted to have a physician as accomplished and as well respected nationally and internationally as Dr. Abbud-Filho involved in our program of preventive molecular medicine. Brazil is obviously a huge market. Dr. Abbud-Filho's superb training and demonstrated ability to remain at the cutting edge of medicine, his skill at educating his peers, and the respect he has already earned professionally among his peers and his patients, makes him an ideal partner for GenoMed."
Dr. Moskowitz added, "We are thrilled by the growing number of physicians who are embracing GenoMed's mission of preventive molecular medicine, and who are interested in becoming part of our Clinical Outcomes Improvement Network (TM). We hope in the coming years to capture a significant portion of practicing physicians not only in the United States, but abroad as well. "
The Clinical Outcomes Improvement Program(TM) is designed to enable physicians to improve their patients' health dramatically while positively differentiating a physician's practice in the medical marketplace.
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use. A video version of the company's treatment results for chronic kidney failure is available at 216.234.225.2
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
+1-314-977-0042, or kfischer@genomedics.com
Web site: genomedics.com
. |
